Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALCAINE vs METRONIDAZOLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.
After entry into the cell, metronidazole is reduced by bacterial nitroreductases to form toxic metabolites that damage DNA and inhibit nucleic acid synthesis, leading to cell death.
Ophthalmic anesthesia for procedures such as cataract extraction, tonometry, gonioscopy, and suture removal
Trichomoniasis,Bacterial vaginosis,Amebiasis,Giardiasis,Anaerobic bacterial infections (e.g., intra-abdominal, gynecologic, skin and soft tissue, bone and joint, CNS infections),Helicobacter pylori eradication (in combination therapy),Perioperative prophylaxis for colorectal surgery,Acute diverticulitis,Crohn's disease (off-label),Rosacea (topical),Decubitus ulcers (topical)
1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.
500 mg intravenously every 8 hours or 500 mg orally every 8 hours; for bacterial vaginosis, 500 mg orally twice daily for 7 days; for trichomoniasis, 2 g orally as a single dose.
Terminal elimination half-life: 0.4–1.2 minutes (rapid enzymatic hydrolysis by plasma esterases); clinical significance: ultra-short duration limits systemic toxicity.
8 hours (range 6-10 hours) in adults; prolonged to 18-20 hours in severe hepatic impairment; requires adjustment in cirrhosis.
Hydrolyzed by plasma esterases.
Hepatic metabolism via oxidation and glucuronidation; major cytochrome P450 enzymes: CYP2A6, CYP3A4, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1; also reduced by nitroreductases in some bacteria and human cells.
Renal excretion of parent drug and metabolites: <5% unchanged.
Renal (60-80% unchanged drug), biliary/fecal (6-15% as metabolites, <20% unchanged).
Minimal; <5% bound to plasma proteins.
<20% bound to plasma proteins (albumin).
Not clinically meaningful due to rapid hydrolysis; Vd estimated <0.5 L/kg (low, consistent with high water solubility and rapid clearance).
0.7-1.1 L/kg; Vd increased in edema/ascites; distributes widely including CNS, bone, and abscess cavities.
Ophthalmic topical: negligible systemic absorption (minimal bioavailability); not applicable systemically.
Oral: 80-95% (100% for immediate-release); Topical: <2% systemic; Vaginal: 20-25% systemic after 500 mg dose.
No dose adjustment required; negligible systemic absorption.
For GFR 10-50 m L/min: no adjustment needed; for GFR <10 m L/min: extend interval to every 12 hours if using multiple doses; for intermittent hemodialysis: administer dose after dialysis on dialysis days.
No dose adjustment required; negligible systemic absorption.
For Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: use with caution, consider further dose reduction (e.g., 50% of normal dose every 12 hours) and monitor for toxicity.
1 drop of 0.5% solution topically to the eye, repeated as needed; maximum 1 drop per dose in infants and young children to avoid systemic effects.
Neonates: 15 mg/kg loading dose, then 7.5 mg/kg every 12 hours for <7 days, or every 8 hours for 7-28 days; Infants and children: 7.5 mg/kg every 6 hours (max 4 g/day) for most infections; for amebiasis: 35-50 mg/kg/day in 3 divided doses for 10 days.
No specific adjustment; use lowest effective dose due to potential increased corneal sensitivity and delayed healing.
No specific dose adjustment based solely on age, but monitor renal function; reduce dose if creatinine clearance <10 m L/min as per renal adjustment; use lowest effective dose and monitor for neurotoxicity (e.g., peripheral neuropathy, seizures).
Not for injection or prolonged use; corneal toxicity with repeated or prolonged use.
Carcinogenicity has been observed in mice and rats following chronic administration; however, the relevance to humans is unclear.
Prolonged use may cause corneal epithelial damage and delay wound healing. Avoid contamination of the dropper tip.
May cause peripheral neuropathy and CNS effects including seizures, dizziness, and ataxia; discontinue if abnormal neurologic signs occur.,Carcinogenicity in animal studies; use for shortest duration necessary.,Hepatotoxicity and pancreatitis reported.,Hypersensitivity reactions including Stevens-Johnson syndrome.,May prolong QT interval; use with caution in patients with electrolyte disturbances or taking other QT-prolonging drugs.,Potential for disulfiram-like reaction with alcohol; avoid during therapy and for at least 48 hours after completion.,Possible mutagenicity; avoid use in pregnancy (especially first trimester) unless clearly needed.,May cause metallic taste, nausea, and other GI disturbances.
Hypersensitivity to any component of the formulation.
Hypersensitivity to metronidazole or other nitroimidazole derivatives,First trimester of pregnancy (theoretical risk, though risk appears low),Concomitant use with disulfiram (can cause acute psychosis/confusion),Concomitant use with ethanol or propylene glycol (disulfiram-like reaction)
None known.
Avoid alcohol and alcohol-containing foods (e.g., sauces, vinegars, some desserts) during therapy and for 48 hours after completion. No other significant food interactions.
Proparacaine (ALCAINE) is an ophthalmic local anesthetic. Systemic absorption is negligible after topical ocular administration. No adequate well-controlled studies in pregnant women. Animal studies showed no teratogenic effects at doses up to 0.5 mg/kg (SC). Potential fetal risk unlikely to exceed background risk. No known trimester-specific risks.
Metronidazole crosses the placenta. First trimester: limited human data show no consistent increase in major malformations; however, some studies suggest a possible small risk of oral clefts. Second/third trimester: generally considered low risk; no known fetal toxicity at standard doses. Avoid high doses in first trimester unless essential.
Proparacaine is excreted into breast milk in unknown amounts, but due to minimal systemic absorption, the expected dose to infant is negligible. Manufacturer advises caution. No M/P ratio available.
Metronidazole is excreted into breast milk with an M/P ratio of approximately 0.9. Peak milk concentration occurs 2-4 hours after dose. After single 2 g dose, withholding breastfeeding for 12-24 hours is recommended. Chronic use: monitor infant for diarrhea, candidiasis, or irritability.
No dosing adjustment required for topical ophthalmic use due to negligible systemic absorption and lack of pharmacokinetic alterations in pregnancy.
No specific dose adjustment required in pregnancy; pharmacokinetics unchanged. Standard adult dosing applies. For bacterial vaginosis: 500 mg PO BID x 7 days or 2 g single dose. Avoid high-dose regimens (e.g., for trichomoniasis) in first trimester; use clotrimazole locally if possible.
ALCAINE (proparacaine) is a topical ophthalmic anesthetic. Onset within 20 seconds, duration ~15 minutes. Do not dispense for home use due to risk of corneal toxicity with prolonged use. Use a sterile, single-dose vial to prevent contamination. Monitor for stinging or burning on instillation. Avoid in patients with sulfite allergy (contains sodium bisulfite).
Metronidazole is a nitroimidazole antibiotic effective against anaerobic bacteria and protozoa. It requires acidic environment for activation; thus, avoid concurrent use with antacids or H2 blockers. Monitor for peripheral neuropathy and seizure with prolonged use. Disulfiram-like reaction occurs with alcohol; counsel patients to avoid alcohol during therapy and for 48 hours after last dose. Use caution in hepatic impairment (dose reduction recommended). Intravenous form is irritant; do not co-administer with blood products via same line.
Temporary stinging or burning may occur upon application.,Do not touch the dropper tip to any surface to avoid contamination.,Do not use for more than instructed; prolonged use can damage the cornea.,Remove contact lenses before use and wait at least 15 minutes before reinserting.,Notify your doctor if you have a sulfite allergy.
Avoid alcohol and alcohol-containing products during treatment and for 48 hours after the last dose to prevent severe nausea, vomiting, and flushing.,Take with food to minimize gastrointestinal upset.,Complete the full course even if symptoms improve.,Report numbness, tingling, or seizures immediately.,May cause metallic taste (harmless) and darkening of urine (not clinically significant).
No interactions on record
"Metronidazole is a known inhibitor of CYP3A4, the primary enzyme responsible for metabolizing Osimertinib. Coadministration increases Osimertinib AUC by approximately 30-60%, leading to elevated plasma concentrations that may potentiate adverse effects such as QTc prolongation, interstitial lung disease, and diarrhea. Clinicians should monitor for signs of Osimertinib toxicity and consider dose reduction if concurrent use is unavoidable."
"Metronidazole inhibits CYP3A4, the primary enzyme responsible for the metabolism of ergotamine. Co-administration can lead to significantly elevated ergotamine plasma concentrations, increasing the risk of ergotism—a serious condition characterized by severe vasoconstriction, ischemia, and potential gangrene of the extremities. Patients may present with symptoms such as cold, painful extremities, muscle pain, and paresthesias, requiring immediate intervention."
"Levofloxacin and metronidazole both prolong the QT interval, and their concurrent use can lead to additive effects on cardiac repolarization. This increases the risk of torsade de pointes, a potentially fatal ventricular arrhythmia. Patients with pre-existing QT prolongation, electrolyte disturbances, or bradycardia are at higher risk."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALCAINE vs METRONIDAZOLE, answered by our medical review team.
ALCAINE is a Local Anesthetic that works by Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.. METRONIDAZOLE is a Nitroimidazole Antibiotic that works by After entry into the cell, metronidazole is reduced by bacterial nitroreductases to form toxic metabolites that damage DNA and inhibit nucleic acid synthesis, leading to cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALCAINE and METRONIDAZOLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALCAINE is: 1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.. The standard adult dose of METRONIDAZOLE is: 500 mg intravenously every 8 hours or 500 mg orally every 8 hours; for bacterial vaginosis, 500 mg orally twice daily for 7 days; for trichomoniasis, 2 g orally as a single dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALCAINE and METRONIDAZOLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALCAINE is classified as Category C. Proparacaine (ALCAINE) is an ophthalmic local anesthetic. Systemic absorption is negligible after topical ocular administration. No adequate well-controlled studies in pregnant wom. METRONIDAZOLE is classified as Category A/B. Metronidazole crosses the placenta. First trimester: limited human data show no consistent increase in major malformations; however, some studies suggest a possible small risk of o. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.